Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04318093 | Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure | PHASE2 | COMPLETED | 25 | — | — | Nov 6, 2020 | Jul 19, 2021 | Aug 4, 2022 | 18 | Argentina, Czechia +4 |
Clinically Relevant Hypotension is defined as occurrence of any of the following: * Supine Systolic Blood Pressure (SBP) \<85 mmHg (confirmed by repeat measurement within 30 minutes), regardless of symptoms of hypotension * Supine SBP \<90 mmHg (confirmed by repeat measurement within 30 minutes) AND symptoms of hypotension (eg, dizziness, lightheadedness, etc).
| Arm | Type | Description |
|---|---|---|
| BMS-986259 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-986259 | DRUG | Specified dose on specified days |
| Placebo | OTHER | Specified dose on specified days |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Participants currently hospitalized for acute decompensated heart failure (ADHF) * Participants must be hemodynamically stable, as assessed by the investigat...